Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288251 | 0.83 | EPHX2 (0.41) | TLR2TLR1 | |
| SCHEMBL6777509 | 0.82 | FAAH (0.47) | — | |
| SCHEMBL6279146 | 0.81 | EPHX2 (0.42) | TLR2TLR1 | |
| SCHEMBL7051029 | 0.81 | EPHX2 (0.42) | TLR2TLR1 | |
| SCHEMBL6777814 | 0.81 | EPHX1 (0.44) | — | |
| SCHEMBL6768483 | 0.80 | DRD3 (0.44) | — | |
| SCHEMBL6783628 | 0.79 | FBP1 (0.43) | — | |
| SCHEMBL6283987 | 0.79 | TLR7 (0.42) | TLR2TLR1 | |
| SCHEMBL6773196 | 0.79 | ALDH1A1 (0.39) | — | |
| SCHEMBL6773010 | 0.78 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | claimed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6716988-B2 | 1-PHENOXY-3-NITRO- OR AMINO-4-AMINOALKYLCARBAMYL DERIVATIVES; IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR2 648/4885TLR1 113/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR2 648/4885TLR1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.